[A14-21] Fingolimod (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Last updated 01.10.2014
Project no.:
A14-21
Commission:
Commission awarded on 19.06.2014 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Muscles, bones and joints, Head and nerves
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-87 | Fingolimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A15-48 | Fingolimod (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A15-12 | Fingolimod - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A11-23 | Fingolimod - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A14-43 | Addendum to Commission A14-21 (Fingolimod) | Commission completed |
Federal Joint Committee (G-BA)
2014-12-18 A G-BA decision was published.